NCLEX Review Guide: Gestational Diabetes Mellitus (GDM)

Definition and Development

• Gestational diabetes mellitus (GDM) is glucose intolerance that develops or is first recognized during pregnancy, typically in the second or third trimester. The condition occurs when pancreatic beta cells cannot produce enough insulin to overcome the insulin resistance that normally develops during pregnancy.
• Pregnancy is considered a diabetogenic state due to the placental production of hormones such as human placental lactogen (hPL), estrogen, progesterone, and cortisol, which contribute to insulin resistance.

Risk Factors

• Major risk factors include obesity (BMI ≥30 kg/m²), previous history of GDM, glycosuria, family history of diabetes (especially first-degree relatives), advanced maternal age (>35 years), and previous delivery of a macrosomic infant (>4000g).
• Additional risk factors include polycystic ovary syndrome (PCOS), history of impaired glucose tolerance, hypertension, and certain ethnicities with higher prevalence (Hispanic, African American, Native American, Asian, and Pacific Islander).

Screening Approaches

• Universal screening is recommended between 24-28 weeks gestation for all pregnant women not previously diagnosed with overt diabetes. Early screening (at first prenatal visit) is recommended for women with high-risk factors.
• The screening involves a two-step approach with a 50g glucose challenge test (GCT) followed by a 100g oral glucose tolerance test (OGTT) if the GCT is abnormal, or a one-step approach using a 75g OGTT.

Maternal Complications

• Women with GDM have an increased risk of developing preeclampsia, polyhydramnios, and cesarean delivery. The hyperglycemic environment leads to increased amniotic fluid production and may contribute to hypertensive disorders.
• Long-term complications include a 35-60% increased risk of developing type 2 diabetes within 5-10 years after delivery. Women with GDM also have increased risk for recurrence of GDM in subsequent pregnancies (30-50%).

Fetal and Neonatal Complications

• Macrosomia (birth weight >4000g) is a major complication resulting from maternal hyperglycemia, which causes fetal hyperinsulinemia and excessive fetal growth. This increases risk for shoulder dystocia, birth trauma, and operative delivery.
• Neonatal hypoglycemia occurs in 15-25% of infants born to mothers with GDM due to the abrupt cessation of maternal glucose supply at birth while the newborn continues to produce high levels of insulin. Other complications include hyperbilirubinemia, respiratory distress syndrome, and polycythemia.
• Long-term effects on offspring include increased risk for childhood obesity, impaired glucose tolerance, and metabolic syndrome. These risks are related to both genetic predisposition and intrauterine exposure to hyperglycemia.

Nutritional Management

• Medical nutrition therapy (MNT) is the cornerstone of GDM management, with approximately 80-90% of women with GDM achieving glycemic control through dietary modifications alone. The recommended caloric distribution is 40% carbohydrates, 20% protein, and 40% fat, with emphasis on complex carbohydrates with low glycemic index.
• Recommended caloric intake is typically 30-35 kcal/kg/day for normal-weight women, with adjustments for pre-pregnancy BMI: 25-30 kcal/kg/day for overweight women and 24 kcal/kg/day for obese women. Carbohydrates should be distributed throughout the day in 3 moderate meals and 2-4 snacks to prevent postprandial hyperglycemia.

Physical Activity

• Regular moderate exercise for 30 minutes most days of the week is recommended for women with GDM who have no medical or obstetrical contraindications. Exercise improves insulin sensitivity and helps achieve glycemic control.
• Appropriate activities include walking, swimming, stationary cycling, and specially designed pregnancy exercise programs. Women should avoid activities with high risk of falls or abdominal trauma.

Pharmacological Management

• Insulin therapy is initiated when dietary and exercise interventions fail to maintain target glucose levels: fasting <95 mg/dL, 1-hour postprandial <140 mg/dL, or 2-hour postprandial <120 mg/dL. Human insulin is preferred as it does not cross the placenta.
• Oral hypoglycemic agents, particularly metformin and glyburide, are increasingly used as alternatives to insulin. While not FDA-approved for GDM, evidence supports their safety and efficacy, with metformin showing comparable outcomes to insulin in many studies.

Glucose Monitoring

• Self-monitoring of blood glucose (SMBG) is essential for evaluating the effectiveness of the treatment plan. The typical regimen includes testing fasting blood glucose and either 1-hour or 2-hour postprandial levels after each meal.
• Continuous glucose monitoring (CGM) systems may be used in cases of difficult-to-control GDM or when frequent hypoglycemia is a concern, providing more comprehensive data on glucose patterns throughout the day and night.

Blood Glucose Monitoring Procedure

1. Wash hands with soap and water, then dry thoroughly
2. Prepare glucose meter and test strip according to manufacturer's instructions
3. Obtain blood sample from side of fingertip using lancet device
4. Apply blood sample to test strip and wait for result
5. Record result in glucose log, noting time relative to meals
6. Dispose of lancet in sharps container
7. Report patterns of abnormal readings to healthcare provider

Monitoring Protocols

• Women with well-controlled GDM on diet alone typically begin fetal surveillance at 36-37 weeks, while those requiring medication or with additional complications may start earlier at 32-34 weeks. Monitoring includes non-stress tests (NST), biophysical profiles (BPP), and growth ultrasounds.
• Serial ultrasounds are recommended to monitor fetal growth every 3-4 weeks starting from diagnosis, with particular attention to abdominal circumference as an early indicator of macrosomia. Amniotic fluid assessment is important to detect polyhydramnios, which occurs in 10-30% of GDM pregnancies.

Timing and Mode of Delivery

• For women with well-controlled GDM and no complications, delivery is typically recommended at 39-40 weeks gestation. Earlier delivery (37-39 weeks) may be considered for poorly controlled GDM or when complications such as preeclampsia or fetal macrosomia are present.
• Cesarean delivery should be considered when estimated fetal weight exceeds 4500g in diabetic women (4000g in women with additional risk factors) to reduce the risk of shoulder dystocia. Induction of labor may be appropriate between 39-40 weeks even with good glycemic control to reduce the risk of stillbirth and shoulder dystocia.

Immediate Postpartum Management

• Insulin requirements drop dramatically immediately after delivery of the placenta due to the rapid decrease in placental hormones that cause insulin resistance. Women who required insulin during pregnancy typically have their insulin discontinued after delivery, with blood glucose monitoring continued for 24-48 hours.
• Neonates require close monitoring for hypoglycemia, with glucose checks recommended within the first hour of life and continuing until stable. Early and frequent feeding helps maintain neonatal glucose levels, with supplemental glucose administered if levels fall below 40-45 mg/dL.

Long-term Follow-up

• A 75g OGTT is recommended at 4-12 weeks postpartum to identify women with persistent glucose abnormalities. Results are classified as normal, prediabetes (impaired fasting glucose or impaired glucose tolerance), or diabetes according to non-pregnant criteria.
• Women with history of GDM should undergo lifelong screening for diabetes at least every 3 years, or more frequently with additional risk factors. Lifestyle modifications including weight management, healthy diet, and regular physical activity are recommended to reduce the risk of developing type 2 diabetes.

GDM vs. Pre-existing Diabetes in Pregnancy

Diagnostic Tests and Criteria

• One-step approach: Uses a 75g OGTT with diagnosis based on one or more abnormal values (IADPSG criteria). This approach identifies more cases of GDM but may lead to overdiagnosis.
• Two-step approach: Begins with a 50g glucose challenge test (GCT) followed by a 100g OGTT if the GCT is abnormal. Diagnosis requires two or more abnormal values on the OGTT (Carpenter-Coustan criteria).

Treatment Options

• Insulin therapy is considered the gold standard pharmacological treatment for GDM. Different types include rapid-acting (lispro, aspart), short-acting (regular), intermediate-acting (NPH), and long-acting (glargine, detemir) insulins.
• Oral hypoglycemic agents are increasingly used alternatives. Metformin works by decreasing hepatic glucose production and increasing peripheral glucose uptake, while glyburide stimulates pancreatic insulin secretion.

Key Concepts to Master

• Understand the pathophysiology of GDM, particularly how placental hormones contribute to insulin resistance and how this affects maternal and fetal outcomes.
• Know the screening and diagnostic criteria for GDM, including the differences between one-step and two-step approaches and the specific glucose thresholds for each test.
• Master the principles of GDM management, including dietary recommendations, physical activity guidelines, glucose monitoring protocols, and pharmacological interventions.

NCLEX Question Strategies

• For priority questions, remember that maternal safety comes first, followed by fetal wellbeing. For example, treating maternal hypoglycemia takes priority over routine glucose monitoring.
• When answering questions about patient education, focus on practical, specific instructions rather than general statements. For example, specific carbohydrate distribution recommendations are better than general advice to "eat a healthy diet."

Self-Assessment Checklist

• Use this checklist to ensure you've mastered the key concepts related to GDM before your exam.